Hepatitis B Vaccination Guidelines

General Recommendations

• The Centers for Disease Control and Prevention recommends that persons who have completed a hepatitis B vaccination series should not routinely receive additional vaccination, as immunocompetent individuals maintain long-term protection even after antibody levels decline 1, 2
• The Centers for Disease Control and Prevention states that revaccination (booster doses) is not generally recommended for persons with normal immune status who completed the primary vaccine series at any age 3
• Immunocompetent persons who achieved anti-HBs ≥10 mIU/mL after the primary series have long-term protection and do not need further periodic testing or booster doses, according to the Centers for Disease Control and Prevention 4, 5
• There is no evidence that receiving additional vaccine doses is harmful, but it is unnecessary for most people, as stated by the Centers for Disease Control and Prevention 1, 2

Special Populations

• The Centers for Disease Control and Prevention recommends that initial non-responders (anti-HBs <10 mIU/mL after primary series) should receive a complete second 3-dose series on an appropriate schedule, and test anti-HBs 1-2 months after the final dose of the second series 4, 5
• Among initial non-responders, 60-97% will achieve protective levels (≥10 mIU/mL) after a booster dose, according to the American Academy of Pediatrics 6 is replaced with:
• The American Academy of Pediatrics is not the source of this fact, instead: Among initial non-responders, the response rate is between 60-97% after a booster dose 6
• Healthcare personnel with documented complete vaccination but anti-HBs <10 mIU/mL require revaccination with one additional standard dose of HepB vaccine, and test anti-HBs 1-2 months after the booster dose, as recommended by the Centers for Disease Control and Prevention 6 is replaced with:
• The Centers for Disease Control and Prevention recommends that Healthcare personnel with documented complete vaccination but anti-HBs <10 mIU/mL require revaccination with one additional standard dose of HepB vaccine, and test anti-HBs 1-2 months after the booster dose 7
• Hemodialysis patients require annual monitoring and booster dosing, with assessment of need for sometime after vaccination, and administration of a booster dose when anti-HBs levels decline to <10 mIU/mL, according to the Centers for Disease Control and Prevention 8, 7
• Immunocompromised persons, such as HIV-infected persons, hematopoietic stem-cell transplant recipients, and persons receiving chemotherapy, may require annual testing and boosters for ongoing risk, as recommended by the Centers for Disease Control and Prevention 8, 7

Postvaccination Testing

• The Centers for Disease Control and Prevention recommends postvaccination testing 1-2 months after completing the primary series for certain groups, including infants born to HBsAg-positive or HBsAg-unknown mothers, healthcare personnel and public safety workers, hemodialysis patients and predialysis patients, HIV-infected persons, other immunocompromised persons, and sex partners of HBsAg-positive persons 8, 3

Common Pitfalls to Avoid

• The Centers for Disease Control and Prevention advises against routinely revaccinating immunocompetent persons who completed the series, even if antibody levels have declined—they retain immune memory 3
• The Centers for Disease Control and Prevention recommends only accepting dated records as evidence of vaccination—do not rely on patient recall alone 1, 2
• Most persons (88%) maintain immune memory even 30 years after vaccination, responding to challenge doses, according to the American Academy of Pediatrics is replaced with:
• Most persons (88%) maintain immune memory even 30 years after vaccination, responding to challenge doses 6

Management of Low Anti‑HBs Titers After Hepatitis B Vaccination

Initial Booster Strategy

• For adults who have completed the hepatitis B vaccine series but have anti‑HBs < 10 mIU/mL, the CDC recommends administering a single additional standard dose of hepatitis B vaccine and re‑checking anti‑HBs 1–2 months later rather than repeating the full series. 9

Criteria for Full Revaccination

• If anti‑HBs remains < 10 mIU/mL 1–2 months after the booster dose, the CDC advises proceeding with a complete second 3‑dose series (0, 1, and 6 months). This second series is only indicated when the booster fails to achieve protective antibody levels. 9

Efficacy of the Second Series

• Among initial non‑responders who receive the full second 3‑dose series, 44 %–100 % achieve protective anti‑HBs levels (≥10 mIU/mL) after completion, according to Clinical and Molecular Hepatology data. 10

Post‑Revaccination Testing

• The CDC recommends re‑testing anti‑HBs 1–2 months after the third dose of the second series to confirm whether protective antibody levels have been attained. 9

Protection Threshold for High‑Risk Individuals

• For healthcare personnel and other high‑risk groups with ongoing exposure risk, documented anti‑HBs ≥ 10 mIU/mL remains the standard criterion for confirming immunity, as stipulated by CDC guidance. 9